Ruthenium Anticancer Compounds: Challenges and Expectations | Zendy

I. Bratsos | Zendy; S. Jedner | Zendy; Teresa Gianferrara | Zendy; Enzo Alessio | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ruthenium Anticancer Compounds: Challenges and Expectations

Author(s) -

I. Bratsos,

S. Jedner,

Teresa Gianferrara,

Enzo Alessio

Publication year - 2007

Publication title -

chimia international journal for chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.387

H-Index - 55

eISSN - 2673-2424

pISSN - 0009-4293

DOI - 10.2533/chimia.2007.692

Subject(s) - ruthenium , indazole , combinatorial chemistry , anticancer drug , chemistry , imidazole , stereochemistry , pharmacology , medicine , drug , organic chemistry , catalysis

Two ruthenium compounds, namely [ImH]trans-[RuCl4(Im)(dmso-S)] (NAMI-A, Im = imidazole) and [IndH] trans-[RuCl4(Ind)2] (KP1019, Ind = indazole) have already completed phase I clinical trials as anticancer agents. They both have properties different from platinum anticancer drugs: for example, NAMI-A is selectively active against metastases of solid tumors. They show that in the field of anticancer metal drugs a new approach, based on targeted therapies, is possible. After a concise history of ruthenium anticancer compounds, this contribution will focus on ruthenium-dmso complexes and, in particular, on NAMI-A. Particular emphasis is given on the challenges that are inherent to this field: how to develop new anticancer ruthenium compounds and how to select new active compounds that manifest their anticancer activity through non-conventional mechanisms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research